Krystal Biotech FY2024 EPS Estimate Boosted by William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at William Blair increased their FY2024 earnings estimates for Krystal Biotech in a research report issued to clients and investors on Monday, November 4th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of $2.96 for the year, up from their previous estimate of $2.75. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.88 per share. William Blair also issued estimates for Krystal Biotech’s Q4 2024 earnings at $1.15 EPS, Q1 2025 earnings at $1.43 EPS, Q3 2025 earnings at $1.61 EPS, Q4 2025 earnings at $1.50 EPS and FY2025 earnings at $6.13 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.67) earnings per share.

KRYS has been the subject of several other research reports. Stifel Nicolaus increased their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Citigroup increased their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday. Chardan Capital increased their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Evercore ISI increased their price target on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and an average price target of $197.00.

Krystal Biotech Trading Up 1.3 %

Shares of KRYS stock opened at $185.45 on Wednesday. The stock has a market cap of $5.33 billion, a price-to-earnings ratio of 104.77 and a beta of 0.82. The stock has a 50-day moving average of $181.20 and a 200-day moving average of $180.29. Krystal Biotech has a 1-year low of $93.95 and a 1-year high of $219.34.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 14.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KRYS. Price T Rowe Associates Inc. MD boosted its holdings in Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after acquiring an additional 231,255 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Krystal Biotech by 1,972.0% in the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock valued at $22,674,000 after purchasing an additional 117,510 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after purchasing an additional 103,928 shares in the last quarter. Capital World Investors bought a new position in shares of Krystal Biotech in the first quarter valued at approximately $17,285,000. Finally, Public Sector Pension Investment Board bought a new position in shares of Krystal Biotech in the second quarter valued at approximately $10,037,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).